LOGIN  |  REGISTER

InMode to Present at the 25th Annual Needham Growth Conference

January 03, 2023 | Last Trade: US$18.46 0.30 1.65

YOKNEAM, Israel, Jan. 3, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chairman and Chief Executive Officer, Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present virtually at the 25th Annual Needham Growth Conference on Jan. 12, 2023.

The fireside chat, moderated by Mike Matson, Senior Research Analyst, is scheduled for 10:15 am Eastern Time on Thursday, Jan. 12 and will be webcast from InMode's Investor Relations website at https://inmodemd.com/investors/. InMode will also hold one-on-one investor meetings in person on Wednesday, Jan. 11 and virtual meetings on Thursday, Jan. 12. To schedule a meeting, please contact your Needham representative.

For more information about the event, visit InMode's investor relations site here.

About InMode 

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
+ 917-607-8654 

Recursion

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page